Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Feb;7(2):325-333.
doi: 10.1530/EC-17-0249. Epub 2018 Jan 9.

Coagulation and fibrinolysis in hyperparathyroidism secondary to vitamin D deficiency

Laura P B Elbers  1   2 , Marije Wijnberge  1   2   3 , Joost C M Meijers  4   5 , Dennis C W Poland  6 , Dees P M Brandjes  1   2 , Eric Fliers  7 , Victor E A Gerdes  1   2
Affiliations

Coagulation and fibrinolysis in hyperparathyroidism secondary to vitamin D deficiency

Laura P B Elbers et al. Endocr Connect. 2018 Feb.

Abstract

Introduction: Abnormal coagulation tests have been observed in patients with primary hyperparathyroidism (HPT) suggesting a prothrombotic effect of parathyroid hormone (PTH). Vitamin D deficiency (VIDD) is the most frequent cause of secondary HPT. Aim of our study was to investigate the influence of HPT secondary to moderate-to-severe VIDD and vitamin D replacement on the coagulation and fibrinolysis system.

Subjects and methods: Prospective cohort study of patients with vitamin D <25 nmol/L with and without HPT, and a control group of patients on vitamin D suppletion. At baseline and after 2 months of vitamin D suppletion (900,000 IU in 2 months), endocrine and coagulation markers were measured.

Results: 59 patients with VIDD of which 34 had secondary HPT and 36 controls were included. After 2 months of suppletion, vitamin D increased by 399% (VIDD with HPT), 442% (all patients with VIDD) and 6% (controls). PTH decreased by 34% (VIDD with HPT, P < 0.01 for decrease), 32% (all VIDD, P < 0.01) and increased by 8% in the controls (P-values: <0.01 for relative changes between VIDD with HPT or all VIDD patients vs controls). Relative changes in PT, aPTT, fibrinogen, Von Willebrand factor, factors VII, VIII and X, thrombin generation, TAFI, clot-lysis time and d-dimer were not different between patients with VIDD with HPT or all VIDD vs controls.

Discussion: Secondary HPT due to VIDD does not have a prothrombotic effect. In contrast with previous reports, PTH does not seem to influence coagulation or fibrinolysis, which is relevant because of the high prevalence of VIDD.

Keywords: coagulation; fibrinolysis; parathyroid hormone; secondary hyperparathyroidism; vitamin D deficiency.

PubMed Disclaimer

References

    1. Andersson P, Rydberg E, Willenheimer R. Primary hyperparathyroidism and heart disease – a review. European Heart Journal 2004. 25 1776–1787. (10.1016/j.ehj.2004.07.010) - DOI - PubMed
    1. Hedback G, Oden A. Increased risk of death from primary hyperparathyroidism – an update. European Journal of Clinical Investigation 1998. 28 271–276. (10.1046/j.1365-2362.1998.00289.x) - DOI - PubMed
    1. Kiernan TJ, O’Flynn AM, McDermott JH, Kearney P. Primary hyperparathyroidism and the cardiovascular system. International Journal of Cardiology 2006. 113 E89–E92. (10.1016/j.ijcard.2006.05.033) - DOI - PubMed
    1. Pepe J, Cipriani C, Sonato C, Raimo O, Biamonte F, Minisola S. Cardiovascular manifestations of primary hyperparathyroidism: a narrative review. European Journal of Endocrinology 2017. 177 R297–R308. (10.1530/EJE-17-0485) - DOI - PubMed
    1. Farahnak P, Larfars G, Sten-Linder M, Nilsson IL. Mild primary hyperparathyroidism: vitamin D deficiency and cardiovascular risk markers. Journal of Clinical Endocrinology and Metabolism 2011. 96 2112–2118. (10.1210/jc.2011-0238) - DOI - PubMed

LinkOut - more resources